 LAUSANNE, Switzerland--BUSINESS WIRE--ADC Therapeutics SA NYSE: ADCT, a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of potent and targeted antibody drug conjugates ADCs for patients with hematological malignancies and solid tumors, today reported financial results for the fourth quarter and fiscal year ended December 31, 2020 and provided business updates. The ADC Therapeutics team is well-positioned to execute on our goals 